Entrada Therapeutics, Inc.

NasdaqGM:TRDA Stock Report

Market Cap: US$245.2m

Entrada Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:TRDA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Sep 26SellUS$1,905,768MPM BioImpact LLCCompany259,837US$7.41
03 Sep 26SellUS$617,379MPM BioImpact LLCCompany86,482US$7.19
31 Aug 26SellUS$615,777MPM BioImpact LLCCompany86,914US$7.20
26 Aug 26SellUS$461,546MPM BioImpact LLCCompany62,714US$7.54
10 Aug 26SellUS$1,078,9375AM Venture Management, LLCCompany155,255US$7.00
07 Aug 26SellUS$431,8295AM Venture Management, LLCCompany62,811US$7.00
31 Jul 26SellUS$807,0275AM Venture Management, LLCCompany116,474US$6.93
20 May 26BuyUS$29,316Bernhardt G. ZeiherIndividual5,000US$5.86
20 Nov 25BuyUS$261,846Baker Bros. Advisors LPCompany28,867US$9.07
14 Nov 25SellUS$1,760,0005AM Venture Management, LLCCompany200,000US$8.80
12 Nov 25BuyUS$1,352,587Baker Bros. Advisors LPCompany178,044US$7.95

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of TRDA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders645,9701.79%
General Public1,191,9773.31%
Public Companies2,569,1157.13%
Hedge Funds5,072,73014.1%
VC/PE Firms7,669,76521.3%
Institutions18,907,42752.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 84.1% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.1%
Baker Bros. Advisors LP
5,072,730US$34.5m0%0.17%
10.8%
MPM BioImpact LLC
3,885,115US$26.4m210%1.77%
10.5%
5AM Venture Management, LLC
3,784,650US$25.7m-6.7%6.63%
7.16%
BlackRock, Inc.
2,583,333US$17.6m9.52%no data
7.13%
Roche Holding AG
2,569,115US$17.5m0%no data
4.83%
MRL Ventures Fund LLC
1,739,768US$11.8m0%2.42%
3.99%
Vanguard Capital Management, LLC
1,437,280US$9.8m1.73%no data
2.94%
TCG Crossover Management, LLC
1,060,230US$7.2m-53.7%0.18%
2.65%
Wellington Management Group LLP
954,419US$6.5m-7.77%no data
2.12%
Millennium Management LLC
763,959US$5.2m47.1%no data
2.11%
StepStone Group Inc.
761,277US$5.2m0%0.28%
1.99%
Geode Capital Management, LLC
717,430US$4.9m7.5%no data
1.93%
AQR Capital Management, LLC
694,851US$4.7m808%no data
1.65%
State Street Investment Management
596,677US$4.1m11.8%no data
1.5%
T. Rowe Price Group, Inc.
542,316US$3.7m3.09%no data
1.14%
JP Morgan Asset Management
411,283US$2.8m251,000%no data
1.11%
Acadian Asset Management LLC
400,862US$2.7m20.3%no data
1.09%
Citadel Advisors LLC
394,323US$2.7m83.4%no data
1.04%
Dimensional Fund Advisors LP
376,136US$2.6m15.9%no data
0.86%
Northern Trust Global Investments
309,942US$2.1m31.9%no data
0.84%
Jacobs Levy Equity Management Inc
303,459US$2.1m-9.12%0.01%
0.83%
Nantahala Capital Management, LLC
300,575US$2.0m88.7%0.12%
0.7%
Vanguard Portfolio Management, LLC
254,130US$1.7m15.3%no data
0.59%
Dipal Doshi
213,565US$1.5m3.62%no data
0.55%
Charles Schwab Investment Management, Inc.
197,136US$1.3m-8.2%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 10:57
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Entrada Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ioannis SouroutzidisCantor Fitzgerald & Co.
Paul ChoiGoldman Sachs
Debjit ChattopadhyayGuggenheim Securities, LLC